Global CINV Existing and Pipeline Drugs Market: Snapshot

In the last few years, the cases of cancer has been increasing at a tremendous rate in the next few years. Nausea and vomiting are considered as the common side effects that are associated with the chemotherapy of cancer. The CINV existing and pipeline drugs market is projected to witness a healthy growth in the next few years, thanks to the introduction of two new drugs, namely rolapitant and SUSTOL (extended generic granisetron). Furthermore, the rising number of mergers and acquisitions and the rising focus of the key players on the development of new products are projected to enhance the growth of the global CINV existing and pipeline drugs market in the next few years.

Developments in Research Activities to Encourage Market Growth in Near Future

According to the market research study published by Transparency Market Research, in 2013, the global market for CINV existing and pipeline drugs was worth US$1.28 bn and is projected to reach a value of US$1.88 bn by the end of year 2020. The market is estimated to register a healthy 5.70% CAGR between 2014 and 2020.

A significant rise in the research and development activities for cancer and the rising focus on the development of new drugs are some of the key factors that are projected to encourage the growth of the global CINV existing and pipeline drugs market in the next few years. In addition to this, the launch of new drugs and the rapid development of the healthcare industry are projected to enhance the growth of the market in the next few years. On the other hand, the low awareness among consumers regarding the availability of new and effective drugs and treatments are projected to accelerate the growth of the market in the next few years. 

North America to Lead Global CINV Existing and Pipeline Drugs Market

The global market for CINV existing and pipeline drugs has been categorized on the basis of geography into the Middle East and Africa, Latin America, North America, Asia Pacific, and Europe. In the last few years, North America accounted for a large share of the market and is projected to remain in the similar situation in the next few years. The strong growth of this region can be attributed to the expected approval of rolapitant and SUSTOL in the year 2015 and 2016. Europe is projected to hold the second position in the next few years. Furthermore, the rising incidence of several types of cancer is projected to accelerate the growth of the CINV existing and pipeline drugs market across Asia Pacific in the next few years. In addition to this, the rising contribution from China and India is another major factor that is predicted to enhance the growth of this region in the next few years.

The global market for CINV existing and pipeline drugs is competitive in nature and is projected to witness a high level of competition in the next few years. The launch of new drugs and the growing focus on the research and development activities are projected to accelerate the growth of the overall market in the next few years. Furthermore, the rising mergers and acquisitions is likely to enhance the growth of the market in the next few years. Some of the key players operating in the CINV existing and pipeline drugs market across the globe are Merck & Co., Inc., GlaxoSmithKline plc, Heron Therapeutics, Inc., Helsinn Holding S.A., and Tesaro, Inc. Furthermore, some of the generic manufacturers operating in the market are Baxter Healthcare, Sandoz (Novartis AG), Orchid Healthcare, Mylan Pharmaceuticals, Inc., Barr Laboratories, Inc., Teva Pharmaceuticals, and Sun Pharma.

Global Chemotherapy-Induced Nausea And Vomiting Market: Brief Overview

Chemo therapy induced nausea and vomiting significantly affects the treatment of patients who are suffering from cancer and undergoing chemotherapy. Nausea and vomiting are the side effects which are commonly associated with chemotherapy and may occur within 24 hours of chemotherapy or between 24 hours and five days after chemotherapy. With increasing and continuous rise in the number of people suffering from cancer and therefore an increasing number of people undergoing chemotherapy, it is estimated that the global CINV market will witness a healthy growth in the future. Approximately 14.1 million people across the globe have been diagnosed with cancer in 2012 as per and online cancer database GLOBALCAN. This market is anticipated to reach an evaluation of US$1.88 bn by 2020.

As CINV can be an obstruction to the progress of cancer patients undergoing chemotherapy, the demand for CINV drugs is increasing rapidly. It has become absolutely crucial for oncologists to prescribe the correct drug for treating chemotherapy-induced nausea and vomiting to alleviate the discomfort and pain among patients as well as to be able to carry out further treatment without any delay.

Global Chemotherapy-Induced Nausea And Vomiting Pipeline Drugs Market:  Trends and Opportunities

At present the effect of drugs which are available in the market in order to manage chemotherapy-induced nausea and vomiting (CINV) are: Aloxi (palonosetron), Zofran generic (ondansetron), Kytril generic (granisetron), Emend (aprepitant) and Akynzeo (netupitant-palonosetron FDC). It is expected that in the years to come two new drugs will be introduced. They are: rolapitant and SUSTOL (APF-530). The approval of drugs such as rolapitant and SUSTOL is driving the growth of the global chemotherapy-induced nausea and vomiting drugs market. With several new drugs in the pipeline, it is expected that the future of the chemotherapy induced nausea and vomiting drugs market will be bright, and it will encourage doctors to prescribe new drugs. The approval of new drugs will also help the market to grow. On the other hand, the patent expiry of leading drugs such as Emend, Aloxi, and others is expected to negatively impact the revenue of the chemotherapy-induced nausea and vomiting drugs market.

Global Chemotherapy-Induced Nausea And Vomiting Market: Geographical Analysis

On the basis of geography, the global chemotherapy-induced nausea and vomiting drugs market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Of these, North America has been leading in terms of revenue within the CINV drugs market. This is on account of the approval of important drugs such as Rolapitant and SUSTOL. The launch of pipeline drugs for chemotherapy-induced nausea and vomiting in Europe is also expected to drive the market in Europe. Apart from these two regions the growing incidences of various types of cancer in the Asia Pacific as well as the Rest of the World will ensure that both of these regions will be promising markets for  chemotherapy induced nausea and vomiting drugs market. Emerging economies such as China and India are striving to achieve improved and efficient healthcare infrastructure. This in turn is expected to bode well for the chemotherapy-induced nausea and vomiting drugs market in the Asia Pacific region.

Global Chemotherapy-Induced Nausea And Vomiting Drugs Market: Companies Mentioned

The global chemotherapy-induced nausea and vomiting drugs market is characterized by a number of generic manufacturers in the vendor landscape. They are: Barr Laboratories, Inc., Baxter Healthcare, Sun Pharma, Teva Pharmaceuticals Mylan Pharmaceuticals, Inc., Sandoz (Novartis AG), and Orchid Healthcare. Some of the other important companies within the global chemotherapy induced nausea and vomiting drugs market are: Heron Therapeutics, Inc., Helsinn Holding S.A., Merck & Co., Inc., GlaxoSmithKline plc,  and Tesaro, Inc.

.